PubRank

A Rumley

Author PubWeight™ 114.59‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000 3.90
2 Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002 3.63
3 Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke 1999 2.89
4 von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2002 2.66
5 Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003 2.63
6 Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001 2.43
7 Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999 2.08
8 Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study. Eur Heart J 2000 2.08
9 Acute exercise and markers of endothelial injury in peripheral arterial disease. Eur J Vasc Endovasc Surg 1997 2.07
10 Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med 2008 2.06
11 Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001 1.96
12 Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 1997 1.72
13 A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemost 2007 1.69
14 Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001 1.63
15 The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur Heart J 1993 1.60
16 Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J 1996 1.59
17 Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in Type 2 diabetic men with and without coronary heart disease. Diabetologia 2004 1.46
18 Fetal corticotrophin-releasing hormone mRNA, but not phosphatidylserine-exposing microparticles, in maternal plasma are associated with factor VII activity in pre-eclampsia. J Thromb Haemost 2007 1.43
19 Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 1995 1.38
20 Increased fetal hemoglobin in insulin-treated diabetes mellitus contributes to the imprecision of glycohemoglobin measurements. Clin Chem 1993 1.35
21 Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol 1996 1.29
22 Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 2004 1.24
23 Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1999 1.17
24 Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997 1.17
25 Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men. J Thromb Haemost 2009 1.16
26 Neuroendocrine activation after acute myocardial infarction. Br Heart J 1988 1.16
27 Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993 1.14
28 Secondhand smoke (SHS) exposure is associated with circulating markers of inflammation and endothelial function in adult men and women. Atherosclerosis 2009 1.10
29 C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001 1.08
30 Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997 1.08
31 Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 2008 1.07
32 Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. QJM 2008 1.07
33 Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J Thromb Haemost 2007 1.06
34 Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study. Circulation 1998 1.05
35 Lifestyle and hemostatic risk factors for ischemic heart disease : the Caerphilly Study. Arterioscler Thromb Vasc Biol 2000 1.05
36 C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol 2004 1.03
37 Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease. Atherosclerosis 1993 1.02
38 Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events. Thromb Haemost 1999 1.01
39 Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study. Thromb Haemost 2000 0.98
40 Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein--a cross-sectional population survey. Thromb Haemost 2001 0.98
41 Socioeconomic inequalities in coronary heart disease risk in older age: contribution of established and novel coronary risk factors. J Thromb Haemost 2009 0.95
42 Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart 2002 0.94
43 Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1997 0.93
44 Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters. Int J Obes (Lond) 2007 0.93
45 Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study. Eur Heart J 1998 0.92
46 Determinants of fibrin D-dimer in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1995 0.92
47 Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. J Thromb Haemost 2004 0.91
48 Haemostasis in ischaemic stroke and vascular dementia. Blood Coagul Fibrinolysis 2001 0.91
49 Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb Haemost 2000 0.90
50 Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Int J Cardiol 1995 0.89
51 Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 1998 0.89
52 Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in men and women: the Edinburgh Artery Study. Atherosclerosis 2001 0.88
53 Femoral atherosclerosis in an older British population: prevalence and risk factors. Atherosclerosis 2000 0.88
54 A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost 2004 0.88
55 Early life growth and hemostatic factors: the Barry Caerphilly Growth study. Am J Epidemiol 2008 0.87
56 Thrombogenesis in mitral regurgitation and aortic stenosis. Angiology 1996 0.87
57 Are atrial fibrillation guidelines altering management? A community based study. Scott Med J 2005 0.87
58 The prevalence and analysis of risk factors for age-related macular degeneration: 18-year follow-up data from the Speedwell eye study, United Kingdom. Eye (Lond) 2011 0.86
59 Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002 0.86
60 Effects of acute insulin-induced hypoglycaemia on haemostasis, fibrinolysis and haemorheology in insulin-dependent diabetic patients and control subjects. Clin Sci (Lond) 1991 0.86
61 Plasma lipid peroxides: relationships to cardiovascular risk factors and prevalent cardiovascular disease. QJM 2004 0.86
62 Statin therapy and the acute inflammatory response after coronary artery bypass grafting. Am J Cardiol 2001 0.85
63 Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thromb Haemost 1995 0.85
64 Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables. Thromb Haemost 1999 0.85
65 Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011 0.85
66 Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998 0.84
67 A performance evaluation of commercial fibrinogen reference preparations and assays for Clauss and PT-derived fibrinogen. Thromb Haemost 2002 0.84
68 Endotoxin, cytokines and lipid peroxides in children with intussusception. Br J Surg 2001 0.83
69 Prospective study of circulating soluble CD40 ligand concentrations and the incidence of cardiovascular disease in a nested prospective case-control study of older men and women. J Thromb Haemost 2011 0.83
70 Sex differences in the relationship between inflammatory and hemostatic biomarkers and metabolic syndrome: British 1958 Birth Cohort. J Thromb Haemost 2011 0.83
71 Fibrin D-dimer, markers of coagulation activation and the risk of major ischaemic heart disease in the caerphilly study. Thromb Haemost 2001 0.83
72 Comparison of metabolic responses to laparoscopic and minilaparotomy cholecystectomy. Br J Surg 1993 0.83
73 Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 1995 0.83
74 Lifestyle factors and coagulation activation markers: the Caerphilly Study. Blood Coagul Fibrinolysis 2001 0.83
75 Associations of plasma fibrinogen assays, C-reactive protein and interleukin-6 with previous myocardial infarction. J Thromb Haemost 2003 0.82
76 Fibrinogen and its degradation products as thrombotic risk factors. Ann N Y Acad Sci 2001 0.82
77 The effect of fibrinogen genotype on fibrinogen levels after strenuous physical exercise. Thromb Haemost 2002 0.82
78 Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study. Thromb Haemost 1999 0.82
79 A longitudinal study of the relationships between haemostatic, lipid, and oestradiol changes during normal human pregnancy. Thromb Haemost 1999 0.81
80 Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 1992 0.81
81 Plasma fibrinogen, haemostatic factors and prediction of peripheral arterial disease in the Edinburgh Artery Study. Blood Coagul Fibrinolysis 2000 0.81
82 Prospective study of seasonal patterns in hemostatic factors in older men and their relation to excess winter coronary heart disease deaths. J Thromb Haemost 2012 0.80
83 Anticoagulation with warfarin downregulates inflammation. J Thromb Haemost 2003 0.80
84 Skin microvascular vasodilatory capacity in offspring of two parents with Type 2 diabetes. Diabet Med 2001 0.80
85 Oral contraceptives and venous thromboembolism. Lancet 1997 0.80
86 Is diastolic dysfunction associated with thrombogenesis? A study of circulating markers of a prothrombotic state in patients with coronary artery disease. Int J Cardiol 1995 0.79
87 Long-term use of the low molecular weight heparin tinzaparin in haemodialysis. Haemostasis 1997 0.79
88 Relation of haemostatic, fibrinolytic, and rheological variables to the angiographic extent of peripheral arterial occlusive disease. Int Angiol 1995 0.79
89 Variation in cardiovascular risk factors by angiographic site of lower limb atherosclerosis. Eur J Vasc Endovasc Surg 1996 0.79
90 Hemostatic abnormalities associated with obesity and the metabolic syndrome. J Thromb Haemost 2005 0.79
91 Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease. Atherosclerosis 1995 0.79
92 Systemic effects of polymethylmethycrylate in total knee replacement: A prospective case-control study. Bone Joint Res 2014 0.78
93 Haemostatic factors, atherosclerosis and risk of abdominal aortic aneurysm. Blood Coagul Fibrinolysis 1996 0.78
94 Haemostatic factors and risk of varicose veins and chronic venous insufficiency: Edinburgh Vein Study. Blood Coagul Fibrinolysis 2000 0.78
95 Clinical, biochemical, and rheologic factors affecting the outcome of infrainguinal bypass grafting. J Vasc Surg 1996 0.77
96 The role of haematological factors in diabetic peripheral arterial disease: the Edinburgh artery study. Br J Haematol 1999 0.77
97 Haemostatic and rheological factors as predictors of restenosis following percutaneous transluminal angioplasty. Eur J Vasc Endovasc Surg 1997 0.77
98 Haemostatic and rheological factors in intermittent claudication: the influence of smoking and extent of arterial disease. Br J Haematol 1996 0.76
99 Randomized controlled trial of antioxidants in intermittent claudication. Vasc Med 1997 0.76
100 High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC. Thromb Haemost 1996 0.75
101 Collapse during basketball "marathon". Br J Sports Med 1986 0.75
102 C-reactive protein, idiopathic venous thromboembolism and hormone replacement therapy. Thromb Haemost 2000 0.75
103 Fibrinogen and markers of fibrinolysis and endothelial damage following resolution of critical limb ischaemia. Eur J Vasc Endovasc Surg 1995 0.75
104 Relation of haemostatic, fibrinolytic, and rheological variables to the angiographic extent of peripheral arterial occlusive disease. Int Angiol 1995 0.75
105 Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease. J Thromb Haemost 2004 0.75
106 Smoking, haemostatic factors and the severity of aorto-iliac and femoro-popliteal disease. Thromb Haemost 1996 0.75
107 Influence of graft material on blood rheology and plasma biochemistry following insertion of an infrainguinal bypass graft. Br J Surg 1998 0.75
108 Moderate weight reduction improves red cell aggregation and factor VII activity in overweight subjects. Int J Obes Relat Metab Disord 1997 0.75
109 Percutaneous angioplasty, endothelial markers, and fibrin turnover. J Endovasc Surg 1994 0.75
110 Clinical benefit of fibrinogen evaluation. Blood Coagul Fibrinolysis 1999 0.75
111 A British emergency nurse observes in the United States. J Emerg Nurs 1992 0.75
112 The relative power of heat-precipitation nephelometric and clottable (Clauss) fibrinogen in the prediction of ischaemic heart disease: the Caerphilly and Speedwell studies. Br J Haematol 1998 0.75
113 Effects of moderate weight loss on anginal symptoms and indices of coagulation and fibrinolysis in overweight patients with angina pectoris. Eur J Clin Nutr 2002 0.75
114 Dementia and statins. Lancet 2001 0.75
115 Effect of chronic angiotensin II type I receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic variables in patients with heart failure. Thromb Haemost 2001 0.75
116 Smoking, hemorheologic factors, and progression of peripheral arterial disease in patients with claudication. J Vasc Surg 1998 0.75